Overview
- Abridge announced Thursday that Nvidia will co‑develop a purpose‑built foundation model for doctor‑patient conversations and that Eli Lilly made a strategic investment in the company.
- Nvidia’s Nemotron open model family will be fine‑tuned with Abridge’s de‑identified clinical data and the resulting model will run exclusively inside Abridge’s platform, with deployment expected later in 2026.
- The company said the expanded platform will add voice interactions, pre‑visit chart synthesis, real‑time clinical decision support, automatic billing code generation, and tools to surface clinical trial candidates.
- Abridge says it is already live across hundreds of health systems and handles more than 100 million clinical conversations a year, claims that underpin its commercial ties but also broaden its regulatory exposure.
- Health systems and privacy experts warn the shift from notes to billing and care decisions raises risks around patient consent, HIPAA agreements, data security, accuracy of AI‑generated records, and legal liability that hospitals must address.